FUNDING
Company Profile
Triveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
Founded 2023Waltham, Massachusetts$272M raised
Investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Compare with
vs Tenon Medicalvs Jupiter Neurosciencesvs Ollin Biosciencesvs Assort Healthvs Scribe Therapeuticsvs Celea Therapeuticsvs PureTechvs OneMedNetvs Encore Medicalvs Flare Therapeuticsvs AEON Biopharmavs Apnimedvs Shionogivs Sanofivs Drug Farmvs Attovia Therapeuticsvs Chai Discoveryvs Colossal Biosciences
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Jun 17, 2026 | Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics | $65M | — | Story → |
Triveni Bio FAQ
- How much has Triveni Bio raised?
- Triveni Bio has raised approximately $272M in total funding to date.
- Is Triveni Bio publicly traded?
- No. Triveni Bio is privately held.
- Who are Triveni Bio's investors?
- Triveni Bio's investors include Atlas Venture, Cormorant Asset Management, Ascenta Capital, Janus Henderson Investors, Deep Track Capital, OrbiMed, Viking Global Investors, Fidelity Management & Research.
Coverage Timeline
newest firstAll Coverage
FUNDING$65M
Triveni Bio Raises $65M for Antibody Therapeutics in Immunology
Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.
FUNDING
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
FUNDING$65M
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.